Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience - O'Brien, Susan; Furman, Richard R.; Coutre, Steven; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie; Sharman, Jeff; Wierda, William; Jones, Jeffrey; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; et al. (Blood, 2018)
Keywords: Adenine - analogs & derivatives; Adult; Aged; Aged, 80 and over; Clinical Trials and Observations; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - metabolism; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Male; Middle Aged; Piperidines; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Survival Rate